VIR Stock Vir Biotechnology, Inc.
US · NasdaqGSLast in our picks 2026-10-21 — not in the current list; analysis below is from that screen
Immunology pipeline optionality and a sharply bullish analyst outlook create substantial speculative upside.
Future value: $21.29 (+98.23%) · 6-12 months
Signal breakdown
- ▸Consensus Strong Buy; Barclays set a $30 target.
- ▸Above 50-day MA (+0.94%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (82.5% of range) — strength
- ▸~98% upside to price target
Is VIR a buy right now?
Trend: VIR is trading above the 50-day average (+2.51%), RSI 64 — neutral momentum, with a 3-month return of +24.75%.
Valuation & quality: Vir Biotechnology, Inc. trades on forward P/E -4.4, price-to-book 1.90; fundamentals show net margin -83.0%, return on equity -26.1%, revenue growth 19582.5% year on year.
Analyst consensus: 9 analysts have a mean 12-month price target of $21.00 (+90.2% vs the last close; range $15.00 – $30.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 5) — Immunology pipeline optionality and a sharply bullish analyst outlook create substantial speculative upside.
Computed from end-of-day data; not personal advice.
Our track record with VIR
First flagged in our daily picks as STRONG BUY on 2026-10-21 at $10.74 — +2.8% since.
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -1.40% | +14.10% | -6.70% | +6.80% | -15.00% | +26.30% | +2.20% | -1.30% |
Fundamentals
Analyst price target
Technical signals
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Sector: Healthcare · Industry: Biotechnology · United States · 367 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.